Can-Fite BioPharma (NYSE:CANF) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANFGet Free Report) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

Several other analysts also recently issued reports on the company. D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Can-Fite BioPharma in a research report on Tuesday, December 31st. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Can-Fite BioPharma in a report on Tuesday, November 12th.

View Our Latest Report on CANF

Can-Fite BioPharma Trading Down 4.8 %

Shares of NYSE CANF opened at $1.39 on Monday. The company’s 50-day moving average price is $1.61 and its 200 day moving average price is $2.12. The stock has a market cap of $4.92 million, a price-to-earnings ratio of -0.78 and a beta of 1.33. Can-Fite BioPharma has a 52 week low of $1.29 and a 52 week high of $4.69.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers grew its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANFFree Report) by 58.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,880 shares of the company’s stock after purchasing an additional 9,935 shares during the period. Rhumbline Advisers owned approximately 0.76% of Can-Fite BioPharma worth $44,000 as of its most recent SEC filing. Institutional investors and hedge funds own 21.00% of the company’s stock.

About Can-Fite BioPharma

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.

Featured Stories

Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.